Wall Street analysts’ estimates
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.
The above chart compares changes in analysts’ recommendations for Bluebird Bio since January 2018.
Bluebird Bio stock has risen ~172.3% in the last 12 months and ~119.5% in 2018 year-to-date. Analysts estimate that the stock could increase 30.7% over the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $211 per share compared to the last price of $161.40 per share on September 5.
As of September 6, there are 21 analysts tracking Bluebird Bio. Five of them have recommended a “strong buy” for the stock, nine have recommended a “buy,” six have recommended a “hold,” and one has recommended a “sell.” The consensus rating for Bluebird Bio stands at 2.14, which represents a “buy” for long-term growth investors, as well as value investors. Changes in analysts’ estimates and recommendations are typically based on changing trends in stock prices and the performance of a company.
The First Trust NYSE Arca Biotechnology ETF (FBT) holds 2.9% of its total investments in Bluebird Bio (BLUE), 3% in BioMarin Pharmaceutical (BMRN), 3.1% in Gilead Sciences (GILD), and 3.3% in Vertex Pharmaceuticals (VRTX).